OMER OMEROS CORP

MIXED Impact: 6/10 8-K
Horizon weeks Filed May 13, 2026 Processed 10d 6h ago SEC 0001437749-26-016718
8-K Item 2.02: Earnings release
Latest settled — T+1d
OMER ▲ 0.00% at T+1d
NEUTRAL call ✗ call lost 0.00% · α vs SPY -0.01% · entry $13.28 → $13.28
Next anchor: T+5d due 4d ago
Last close $11.46 (close May 22) · -13.70% from $13.28 entry
Entry anchored
May 13, 03:59 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α -0.01%
$13.28
settled 10d ago
T+5d
—
call — · α —
—
due 4d ago
T+20d
—
call — · α —
—
in 18d
T+60d
—
call — · α —
—
in 3mo

Price Chart

Loading chart...

Executive Summary

Omeros reported Q1 2026 results with first-ever YARTEMLEA commercial sales of $9.9M net, GAAP net income of $56.1M (vs a $33.5M loss a year ago), and non-GAAP adjusted net loss of $17.1M ($0.24/share) that beat consensus of -$0.28. Revenue slightly missed $10.1M consensus. CMS assigned a J-code effective July 1 and recommended NTAP, signaling improving reimbursement.

Actionable Insight

Monitor YARTEMLEA prescription trends for Q2 and the EMA decision on TA-TMA approval expected mid-2026. NTAP final rule in August could further boost hospital demand.

Key Facts

  • First YARTEMLEA net sales of $9.9M in Q1 2026 (launched Jan 2026)
  • GAAP net income $56.1M vs net loss of $33.5M in Q1 2025
  • Non-GAAP adjusted net loss $17.1M ($0.24/share) beat consensus $-0.28
  • Revenue $9.9M vs consensus $10.1M (miss of ~2%)
  • CMS assigned permanent J-code for YARTEMLEA (effective July 1) and recommended NTAP
  • Cash and short-term investments $135.3M at March 31; only $70.8M debt remaining (2029 Notes)
  • Repurchased 0.4M shares for $4.2M during Q1

Financial Impact

First commercial YARTEMLEA sales of $9.9M; non-GAAP EPS beat consensus by 14%

revenueeps

Risk Factors

  • YARTEMLEA adoption may slow without broader label or EU approval
  • Non-GAAP adjusted operations still unprofitable; cash burn continues
  • Revenue miss could pressure near-term expectations

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-016718
Document: omer20260403_8k.htm0001437749-26-016718
Document: 0001437749-26-016718-index-headers.html0001437749-26-016718
Document: 0001437749-26-016718-index.html0001437749-26-016718
Document: 0001437749-26-016718.txt0001437749-26-016718
8-K Data (Synthetic)0001437749-26-016718
2 reports for OMER
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for OMER — sortable, filterable
Type Now
May 13, 2026
10d ago
8-K
MIXED ★ 6/10
$13.28 $13.28· 0.00%▼ −0.01%$11.46 (−13.70%)
Mar 31, 2026
7w ago
8-K
BULLISH ★ 9/10
$12.08 $10.90▼ −9.77%▼ −9.85%$11.46 (−5.13%)
Showing 2 of 2

US Market Status

Market Closed — Opens Tue (35h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access